News

A Scripps Research team shows that suppressing the activity of certain stress neurons may decrease alcohol use—but not anxiety—in comorbid cases of post-traumatic stress disorder and alcohol use disorder.

Customized-design approach could streamline the design of novel proteins targeting the hard-to-access cell membrane region.

New Scripps Research trial aims to validate the use of wearables in guiding participants to effectively monitor mental, physical and emotional exertion—a strategy called pacing.

Christopher Parker and Giordano Lippi are unraveling the metabolic and protein mechanisms, respectively, that go awry in aging and disease—including Alzheimer’s.

New phospholipid discovery brings researchers closer to understanding how primordial cells emerged during origin of life.

Scripps Research chemists fill a major gap in origin-of-life theories.

Scripps Research scientists discovered antibodies that protect against a host of lethal snake venoms.  

Calibr-Skaggs to partner with AbbVie to support discovery of next-generation sCAR-Ts using genetic medicine-based approaches.

Michael Bollong, Howard Hang and additional researchers will lead projects to uncover new therapeutic options for Crohn’s disease, one of the most common forms of IBD.

Scripps Research team restored neuron-to-neuron connections in human cells.

The method could shed light on what goes awry in numerous brain conditions when neurons are correctly and incorrectly activated or inhibited.

Scripps Research scientists developed a compound that can block a protein previously considered challenging to drug and is implicated in autoimmune diseases, including lupus.

The ALSAM Foundation, founded by the Skaggs family, provides lasting gift to Scripps Research’s drug discovery and development arm.

By investigating a molecule in the brain tied to cellular communication, scientists uncover important information about the proteins that do—and do not—influence alcohol drinking behavior. 

For the last century, institute leaders and renowned scientists have made Scripps Research what it is today: the world’s leading independent and nonprofit biomedical research institute at the forefront of innovation.

Long-acting combination HIV regimens have the potential to transform the future of coordinated HIV clinical care.  A Phase 1 trial has been initiated to evaluate GS-1614 - a novel prodrug of a nucleoside reverse transcriptase translocation inhibitor (NRTTI).

Lay, founder of the global biotech company BioLegend, brings invaluable experience as an industry leader and innovator. 

Scripps Research scientists develop a new, high-resolution technique for finding potential therapeutic targets on proteins in living cells. The findings could lead to more targeted therapeutics for nearly any human disease.

Following approval from Australia’s HREC, the clinical trial investigating UVAX-1107 and UXAX-1197 will initiate in January 2024.  

Scripps Research team modifies the traditional poison picrotoxinin for potential neurological drugs and anti-parasite treatments.

Topol provides an overview of how AI models can improve diagnostic accuracy, liberate clinicians from keyboards and restore the doctor-patient relationship.

Scripps Research scientists and collaborators uncovered the relative effectiveness of different COVID-19 mandates, helping guide public health policy for future viral threats.

Early detection of atrial fibrillation can reduce the risk of stroke and heart failure, but screening people for the condition has been historically challenging.

Scripps Research-designed vaccine could provide broad, enduring protection against influenza A strains, including pandemic strains